In a compelling interview, Dr. Manali Kamdar, an esteemed hematologist and clinical director, highlights the critical importance of timely referral to CAR-T therapy centers for patients with relapsed or refractory large B-cell lymphoma (LBCL). Dr. Kamdar underscores that while allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been a standard curative option, its ineligibility does not automatically preclude patients from benefiting from CAR-T therapy. She emphasizes the necessity of prompt referrals to specialized centers capable of administering CD19-directed CAR-T treatments like lisocabtagene maraleucel (liso-cel), which have shown promising results in improving patient outcomes.

Promising Advances in LBCL Treatment: Insights from Dr. Kamdar

In the golden autumn season, during the 66th American Society of Hematology (ASH) Annual Meeting held in San Diego, California, Dr. Manali Kamdar presented crucial insights into the treatment landscape for relapsed or refractory large B-cell lymphoma (LBCL). As an associate professor of medicine at the University of Colorado, Dr. Kamdar stressed the urgency of referring patients who do not respond well to initial treatments to centers specializing in CAR-T therapy without delay.

Dr. Kamdar pointed out that many patients are often deemed ineligible for allo-HSCT due to factors such as advanced age or frail health, which could expose them to significant risks associated with this procedure. However, she firmly believes that these same patients can safely undergo CAR-T therapy. The manufacturing time required for CAR-T must be considered, making early referral essential. She cited the TRANSCEND-NHL-001 clinical trial, which demonstrated the curative potential of liso-cel in relapsed or refractory LBCL patients over a five-year follow-up period.

Moreover, Dr. Kamdar emphasized that healthcare providers should not equate ineligibility for allo-HSCT with ineligibility for CAR-T therapy. Instead, they should recognize the unique benefits and safety profiles of CAR-T, ensuring that more patients have access to this potentially life-saving treatment.

From a journalist's perspective, Dr. Kamdar's insights underscore a pivotal shift in the approach to treating relapsed or refractory LBCL. Her advocacy for timely referrals and broader eligibility criteria for CAR-T therapy offers hope to many patients who previously had limited options. This forward-thinking approach challenges traditional paradigms and encourages medical professionals to explore innovative treatments that can significantly improve patient outcomes and quality of life. It is a reminder that staying abreast of the latest advancements in oncology can make a profound difference in patient care.